- Leading the Group’s sustainable future by boosting R&D performance
- Improved performance in core businesses including ETC and strong aesthetic exports
[by Ji, Yong Jun] Huons Global reported on May 15 its consolidated financial results for this year's January-March period. The company reported 199.1 billion KRW in consolidated sales, 25.6 billion KRW in operating profit, and 26.1 billion KRW in net profit, reflecting year-on-year changes of -1.4%, -1.5%, and +13.1%, respectively.
에볼루션 바카라 무료 Global said that consolidated revenue for the first quarter fell compared to the same period last year, but with improved performances in the group’s core businesses: growth in ethical drug (ETC) business for 에볼루션 바카라 무료 and strong aesthetic exports for Humedix.
The group improved management efficiency and reduced selling, general, and administrative (SG&A) expenses while increasing R&D investments for future growth, resulting in the operating 에볼루션 바카라 무료 for the first quarter to falling year-over-year.
The 에볼루션 바카라 무료 Group said that R&D investment for the first quarter rose 34% to 17.8 billion KRW from 13.3 billion KRW in the same period last year. The group attributed the increase in R&D spending to efforts to secure key new drug candidates (pipelines) and its clinical trial costs for 에볼루션 바카라 무료 and 에볼루션 바카라 무료lab.
에볼루션 바카라 무료 reported consolidated sales of 145.8 billion KRW, operating profit of 12.8 billion KRW, and net profit of 12.3 billion KRW, reflecting year-on-year changes of -1.3%, +20.1%, and +26%, respectively.
에볼루션 바카라 무료’ ETC business showed improved performance driven by continued growth in chronic disease drugs and increased exports of injections to the U.S. and eye drops to the rest of the world.
On May 2, 에볼루션 바카라 무료 received two U.S. Food and Drug Administration’s (FDA) Abbreviated New Drug Application (ANDA) approvals, the two additions to its five FDA approvals for injections. This accelerates 에볼루션 바카라 무료’ export expansion efforts to North America. The company continued stable performance in CMO business, powered by the increased operation rate of the eye drop line at the second production facility.
에볼루션 바카라 무료 significantly improved its profitability as a result of improved performance of its subsidiaries and cost management efforts. 에볼루션 바카라 무료 reported a consolidated operating profit margin of 8.8% and a separate operating profit margin of 9.8%. This marks the highest quarterly operating profit margin since 2024.
에볼루션 바카라 무료 N, a spin-off of 에볼루션 바카라 무료’ health functional food business newly launched on May 2, turned in a profit in the first quarter with sales of 11.7 billion KRW and an operating profit of 200 million KRW. 에볼루션 바카라 무료LifeSciences drastically reduced the deficit, reporting its first quarter sales of 5.8 billion KRW and operating loss of 50 million KRW.
Humedix, an aesthetic subsidiary of 에볼루션 바카라 무료 Group, reported its first quarter separate sales of 40.1 billion KRW, operating profit of 11.4 billion KRW, and net profit of 13.4 billion KRW, reflecting year-on-year changes of -2.5%, +7.3%, and +45%, respectively.
Humedix's performance growth was driven by filler exports, cosmetics, and active pharmaceutical ingredients (API) businesses. In particular, hyaluronic acid (HA) filler showed strong performance. Since last year, its exports to Brazil have continued to grow, and early this year, the company obtained approvals from Thailand on three filler products. Humedix plans to focus on filler exports, leading to steady 에볼루션 바카라 무료 growth. Humedix's operating profit increased in the first quarter due to improved operating rate of the facility and profitability driven by increased filler exports and API 에볼루션 바카라 무료.
HuM&C, a subsidiary specialized in healthcare components, reported its first quarter consolidated sales of 12.5 에볼루션 바카라 무료 KRW, operating profit of 512 million KRW, and net profit of 302 million, with year-on-year changes of +4.4%, -49.6%, and -76.4%, respectively.
HuM&C’s glass business recorded sales of 7.4 에볼루션 바카라 무료 KRW, a slight decrease from the previous year, on the other hand, the cosmetics business showed significant growth, recording 5.1 에볼루션 바카라 무료 KRW. HuM&C attributed this 77.2% increase to the effects of the business acquisition in the second half of last year. In the second quarter, HuM&C expects to ramp up its production facility’s operation in Vietnam to strengthen its competitiveness in the glass business.
에볼루션 바카라 무료 BioPharma, a subsidiary specializing in botulinum toxin, reported its first quarter sales of 7.2 billion KRW and operating profit of 1.4 billion KRW. Overseas sales of toxin products to Thailand and Iraq have increased, but a decrease in domestic sales resulted in both sales and operating profit falling compared to the same period last year. 에볼루션 바카라 무료 Meditech recorded sales of 13.3 billion KRW and an operating loss of 230 million KRW due to the decrease in exports of medical devices, resulting in a decrease in sales and turning it into a deficit.
Food Assemble, a subsidiary specialized in meal kits, recorded 2.4 에볼루션 바카라 무료 KRW in sales and reduced its deficit with 517 million KRW in operating loss.
에볼루션 바카라 무료lab is actively continuing R&D on human hyaluronidase ‘HLB3-002.’ It is currently undergoing a pivotal Phase 1 clinical trial in South Korea. Following the completion of the trial, 에볼루션 바카라 무료lab plans to apply for approval to MFDS in the second half of this year. Last month,에볼루션 바카라 무료lab announced the result of formulation conversion using ‘HLB3-002’ in a poster presentation at the 2025 Annual Meeting of the American Association for Cancer Research (AACR 2025).
CEO of 에볼루션 바카라 무료 Global, Song Soo-young said, “에볼루션 바카라 무료 Group will deliver tangible results and secure mid- to long-term growth engines by vowing to step up overseas expansion and R&D investment. We will continue to strengthen compliance and legal management and become a global healthcare leading company that continues to thrive on corporate ethics.”
에볼루션 바카라 무료 Global has co-CEOs Yoon Sung-tae and Song Soo-young. Chairman Yoon Sung-tae was appointed as 에볼루션 바카라 무료 Global’s CEO by the board after the 38th annual general meeting of shareholders. Chairman Yoon has been returned to the front lines of management to lead the group’s great leap forward, marking its 60th anniversary this year. His main focus is on expanding its global reach and securing competitive pipelines through R&D.